0001516551-22-000052.txt : 20221123 0001516551-22-000052.hdr.sgml : 20221123 20221123172350 ACCESSION NUMBER: 0001516551-22-000052 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221117 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Skye Bioscience, Inc. CENTRAL INDEX KEY: 0001516551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450692882 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55136 FILM NUMBER: 221417161 BUSINESS ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 410-0266 MAIL ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Emerald Bioscience, Inc. DATE OF NAME CHANGE: 20190325 FORMER COMPANY: FORMER CONFORMED NAME: Nemus Bioscience, Inc. DATE OF NAME CHANGE: 20141030 FORMER COMPANY: FORMER CONFORMED NAME: LOAD GUARD LOGISTICS, INC. DATE OF NAME CHANGE: 20121107 8-K 1 skye-20221117.htm 8-K skye-20221117
FALSE000151655100015165512022-11-172022-11-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): November 17, 2022
 
SKYE BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

 
Nevada 000-55136 45-0692882
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
 
11250 El Camino Real, Suite 100, San Diego, CA 92130
(Address of principal executive offices)
 
(858) 410-0266
(Registrant’s telephone number, including area code)
_________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

Securities registered pursuant to Section 12(b) of the Act:



Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
N/A
N/A
N/A

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 1.01 Entry into a Material Definitive Agreement.
Amendment and Acknowledgment Agreement
On November 17, 2022, Skye Bioscience, Inc. (the "Company") entered into an Amendment and Acknowledgement Agreement (the "Amendment Agreement") with Emerald Health Sciences, Inc. ("Emerald"). Under the terms of the Amendment Agreement, the parties agreed to, among other things, (a) require the Company to prepay certain amounts owed to Emerald under the terms of the Amended and Restated Multi-Draw Credit Agreement, dated April 1, 2020, by and between the Company and Emerald (the “Credit Agreement”), (b) amend the terms of the Credit Agreement to extend the maturity date to the earlier of December 30, 2022 or the Termination Date (as such term is defined in the Credit Agreement), (c) amend the exercise price of the warrants to purchase Company common stock issued to Emerald under the Credit Agreement and rolled over from the Emerald Health Therapeutics, Inc. acquisition (the "Emerald Warrants") to US$0.017 and (d) use good faith efforts to enter into a registration rights agreement between Emerald and the Company.
The foregoing description of the Amendment Agreement does not purport to be complete and is qualified in its entirety by reference to the Amendment Agreement attached hereto as Exhibit 10.1, each of which is incorporated herein by reference.
Item 3.03 Material Modification to Rights of Security Holders.
The disclosure under "Item 1.01 Entry into a Material Definitive Agreement" relating to amending the exercise price for the Emerald Warrants is incorporated by reference into this Item 3.03.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
10.1*
104Cover Page Interactive Data File (embedded within the inline XBRL document)
*Filed herewith



SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                        SKYE BIOSCIENCE, INC.
  
  
Dated: November 23, 2022/s/  Kaitlyn Arsenault
 Name: Kaitlyn Arsenault
 Title: Chief Financial Officer

EX-10.1 2 amendmentandacknowledgemen.htm EX-10.1 Document

AMENDMENT AND acknowledgment agreement

THIS AMENDMENT AND ACKNOWLEDGMENT AGREEMENT (this “Agreement”) is dated as of November 17, 2022.
BETWEEN:
SKYE BIOSCIENCE, INC., a corporation existing under the laws of the State of Nevada,
(“SKYE”)
AND:
EMERALD HEALTH SCIENCES, INC., a corporation existing under the laws of the Province of British Columbia,
(“EHS”).

WHEREAS:
A.EHS and SKYE entered into an Amended and Restated Multi-Draw Credit Agreement on April 1, 2020, as amended (the “Credit Agreement”). Terms used but not defined in this Agreement shall have the meanings ascribed to such term in the Credit Agreement.
B.Pursuant to Section 3.2 of the Credit Agreement, SKYE shall not be permitted any prepayment of the Loan without the prior written consent of EHS.
C.SKYE desires to prepay a portion of the outstanding principal amount of the Loan, including all of the outstanding non-convertible principal amount of the Loan, and all unpaid interest under the Loan accrued through November 18, 2022, as set forth in more detail below and EHS desires to permit such prepayment.
D.EHS and SKYE desire to amend and or waive certain sections of the Credit Agreement as set forth herein.
E.EHS and SKYE desire to agree to reprice certain of the warrants issued to EHS pursuant to the terms of the Credit Agreement.



NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the covenants and agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
1.Prepayment. SKYE will make the following prepayments of principal and interest under the Loan as set forth in the table below (the “Prepayment”) upon the execution of this Agreement:
Convertible Debt*Non-Convertible DebtInterest Accrued (November 17, 2022)Total Principal and Interest Prepayment
US$166,125US$450,000US$328,736.91US$944,861.91
*To be applied to the oldest outstanding tranches first
Following the Prepayment described above, EHS and SKYE acknowledge and agree that the remaining principal and interest under the Loan is as follows:
Convertible DebtNon-Convertible DebtInterest Accrued (as of November 17, 2022)
US$1,848,375US$0US$0

1.Warrants
a.SKYE and EHS acknowledge and agree that EHS holds the following warrants to purchase common shares of SKYE:



i.2,500,000 share purchase warrants each exercisable for one common share of SKYE until November 1, 2023 at a price of US$0.50 per share;
ii.2,500,000 share purchase warrants each exercisable for one common share of SKYE until February 1, 2024 at a price of US$0.50 per share;
iii. 2,500,000 share purchase warrants each exercisable for one common share of SKYE until March 29, 2024 at a price of US$0.50 per share; and
iv. 9,141,486 share purchase warrants each exercisable for one common share of SKYE at a price $0.151 per share until December 29, 2024
(collectively, the "Warrants").
SKYE and EHS agree that the certificates representing each of the Warrants are hereby amended to change the exercise price of each Warrant to US$0.017 per share (provided that all adjustment provisions as set out in each such certificate shall continue in full force and effect and such exercise price will be appropriately adjusted as and when necessary in the future in accordance therewith) and SKYE agrees to forthwith upon the execution of this Agreement take all steps necessary to carry out the amendment of the exercise price of each Warrant and to do or cause to be done such further acts as may be necessary to carry out the amendment of the exercise price of the Warrants.
a.SKYE and EHS will use good faith efforts to enter into a Registration Rights Agreement in form satisfactory to both parties on or before November 25, 2022 providing EHS with customary piggyback registration rights for all shares of common stock of SKYE issuable upon exercise of the Warrants, subject to customary limitations imposed by underwriters.
2.Amendments and Waivers to the Credit Agreement.
a.The definition of “Maturity Date” in Section 1 of the Credit Agreement is deleted in its entirety, is of no further force and effect and is replaced by the following:
“Maturity Date” means the earlier of (a) December 30, 2022 and (b) the Termination Date.
a.The parties waive any obligations or restrictions under the Credit Agreement that are inconsistent with the Prepayment, including without limitation, the obligations and restrictions under Section 3.2 and Section 4.2 of the Credit Agreement.
b.Section 12.1 of the Credit Agreement is removed in its entirety and replaced with the following:
“12.1 Failure to Pay. The Company fails to (a) pay (i) any principal or interest of the Loan when due or (ii) any other amount when due; or (b) issue any Common Shares when issuable hereunder, and such failure, in the case of (b), continues for five Business Days.”
1.Miscellaneous.
a.Successors and Assigns. The provisions of this Agreement shall be binding upon and enure to the benefit of the parties hereto and their respective successors and permitted assigns, provided that no party may assign, delegate or otherwise transfer any of its or his rights, interests or obligations under this Agreement without the prior written consent of the other party.
b.Confidentiality. EHS shall maintain in confidence the matters referred to in this Agreement and shall not make any public disclosure, except to the extent required by applicable law or the requirements of any securities regulatory authority or stock exchange, of the terms of this Agreement without the consent of SKYE, such consent not be unreasonably withheld.
c.Entire Agreement. This Agreement supersedes all prior agreements among the parties hereto with respect to the subject matter hereof and contains the entire



agreement among the parties with respect to the subject matter hereof. EHS acknowledges and agrees that SKYE is not currently in breach of any provisions of the Credit Agreement.
d.Amendments. This Agreement may not be modified or waived, except expressly by an instrument in writing signed by all the parties hereto.
e.Further Assurances. Each of the parties hereto agrees to execute such further and other deeds, documents and assurances and to do such further and other acts as may be necessary to carry out the true intent and meaning of this Agreement fully and effectually.
f.Severability. Each of the covenants, provisions, sections, subsections and other subdivisions hereof is severable from every other covenant, provision, section, subsection and subdivision and the invalidity or unenforceability of any one or more covenants, provisions, sections, subsections and other subdivisions hereof shall not effect the validity or enforceability of the remaining covenants, provisions, sections, subsections or subdivisions hereof.
g.Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement, and the transactions contemplated hereby, shall be governed by the laws of the State of California
h.Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.
i.Headings. All Section headings herein are for convenience of reference only and are not part of this Agreement and no construction or inference shall be derived therefrom.

[Remainder of the page intentionally left blank. Signature page follows.]


IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.


SKYE BIOSCIENCE, INC.


By: /s/ Kaitlyn Arsenault

Name: Kaitlyn Arsenault

Title: Chief Financial Officer
:

Email: [*]

EMERALD HEALTH SCIENCES, INC.





By: /s/ Jim Heppell

Name: Jim Heppell

Title: Chief Executive Officer

Email: [*]





EX-101.SCH 3 skye-20221117.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 skye-20221117_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key EX-101.PRE 5 skye-20221117_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page
Nov. 17, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 17, 2022
Entity Registrant Name SKYE BIOSCIENCE, INC.
Entity Incorporation, State or Country Code NV
Entity File Number 000-55136
Entity Tax Identification Number 45-0692882
Entity Address, Address Line One 11250 El Camino Real
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 410-0266
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001516551
XML 7 skye-20221117_htm.xml IDEA: XBRL DOCUMENT 0001516551 2022-11-17 2022-11-17 false 0001516551 8-K 2022-11-17 SKYE BIOSCIENCE, INC. NV 000-55136 45-0692882 11250 El Camino Real Suite 100 San Diego CA 92130 858 410-0266 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 20 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://skyebioscience.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports skye-20221117.htm amendmentandacknowledgemen.htm skye-20221117.xsd skye-20221117_lab.xml skye-20221117_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "skye-20221117.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "skye-20221117.htm" ] }, "labelLink": { "local": [ "skye-20221117_lab.xml" ] }, "presentationLink": { "local": [ "skye-20221117_pre.xml" ] }, "schema": { "local": [ "skye-20221117.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 21, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "skye", "nsuri": "http://skyebioscience.com/20221117", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "skye-20221117.htm", "contextRef": "iab894b883d16476589cfdbfb80b9c209_D20221117-20221117", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://skyebioscience.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "skye-20221117.htm", "contextRef": "iab894b883d16476589cfdbfb80b9c209_D20221117-20221117", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001516551-22-000052-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001516551-22-000052-xbrl.zip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end